2Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-transretinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol, 2003, 21(12) : 2326-2334.
3Van Oosterom AT, Judson IR, Verweij J, et al. Update of phase Ⅰ study of imatinib(STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 2002 (10), 38(Suppl 5) :S83-87.
4Dagher R, Cohen M, Williams G, et al. Approval summary:imatinib mesylate in the treatmentof metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res ,2002,8(10) : 3034-3038.
5George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol, 2003, 532:141-151.
6Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patientswith chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med, 2002,347(7):481-487.
7Thiede C, Steudel C, Mohr B,et al. Analysis of FLT3-activating mutations in 979 patientswith acute myelogenous leukemia:association with FAB subtypes and identification of subgroups with poor prognosis. Blood,2002,99(12) :4326-4335.
8Gutkind JS. Cell growth control by G protein-coupled receptors:from signal transduction to signal integration. Oncogene, 1998,17(11):1331-1342.
9Fiedler W, Mesters R, Tinnefeld H, et al. A phase Ⅱ clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 2003,102(8) : 2763-2767.
10O'Farrell AM, Abrams TJ, Yuen HA,et al. SU11248 is a novel FLT3 tyrosine kinase nhibitor with potent activity in vitro and in vivo. Blood, 2003,101(9) :3597-3605.
